GSK Facing Headwinds in Established Products but Balanced by Growth Opportunities in Oncology
GlaxoSmithKline (GSK) faces several headwinds in its business, with Advair facing generic pressure and its new two-drug HIV regimen struggling to gain traction. On the latter point, the company must convince skeptical healthcare providers that a two-drug regimen is able to provide similar levels of efficacy to a three-drug regimen without developing drug resistance. I detailed these issues from Gilead’s (GILD) perspective last year.
However, GSK also has several growth opportunities within oncology and vaccines that are offsetting